Table 1.
Assessment of TCR BV (B variable) usage of vaccine-elicited CD8+ A2/NY-ESO-1157–165 multimer T cells and CD4+ DP4/NY-ESO-1157–170 T cells for patient 18
Clone | Vβ | CDR3β | Jβ |
---|---|---|---|
A2 (CD8) | |||
2-5-C | 1 | CAS SPGQGPEQ YFG | 2.7 |
3-4-D | 1 | CAS SPGQGPEQ YFG | 2.7 |
5-5-B | 1 | CAS SPGQGPEQ YFG | 2.7 |
5-6-B | 1 | CAS SPGQGPEQ YFG | 2.7 |
DP4 (CD4) | |||
2-C-10 | (6) | CAS SLVAAEGTQ YFG | 2.5 |
3-B-5 | (6) | CAS SLVAAEGTQ YFG | 2.5 |
5-B-8 | (6) | CAS SLVPDSAYEQ YFG | 2.7 |
8-H-12 | (6) | CAS SLVAAEGTQ YFG | 2.5 |